Literature DB >> 33832971

First multicenter experience using the Silk Vista flow diverter in 60 consecutive intracranial aneurysms: technical aspects.

Mario Martínez-Galdámez1, Yilmaz Onal2, José E Cohen3, Vladimir Kalousek4, Rodrigo Rivera5, Juan Gabriel Sordo5, Daniel Echeverria5, Vitor M Pereira6, Jordi Blasco7, Dikran Mardighian8, Murat Velioglu2, Brian van Adel9, Bill Hao Wang9, J Moshe Gomori10, Andrei Filioglo11, Branimir Čulo4, Jeremy Lynch6, Ali Burak Binboga12, Mehmet Onay12, Jorge Galvan Fernandez13, Miguel Schüller Arteaga13, Jose David Guio7, Pervinder Bhogal14, Levan Makalanda14, Ken Wong14, Mohamed Aggour14, Jean Christophe Gentric15, Vladimir Gavrilovic16, Pedro Navia17, Andrés Fernandez Prieto17, Eva González18, Jesus Aldea19, Jose Luis López19, Antonio Lorenzo-Gorriz20, Thomas Madelrieux21,22, Aymeric Rouchaud21,22, Charbel Mounayer21,22.   

Abstract

BACKGROUND: The aim of this study was to assess the technical success and procedural safety of the new Silk Vista device (SV) by evaluating the intraprocedural and periprocedural complication rate after its use in several institutions worldwide.
METHODS: The study involved a retrospective review of multicenter data regarding a consecutive series of patients with intracranial aneurysms, treated with the SV between September 2020 and January 2021. Clinical, intra/periprocedural and angiographic data, including approach, materials used, aneurysm size and location, device/s, technical details and initial angiographic aneurysm occlusion, were analyzed.
RESULTS: 60 aneurysms were treated with SV in 57 procedures. 66 devices were used, 3 removed and 63 implanted. The devices opened instantaneously in 60 out of 66 (91%) cases and complete wall apposition was achieved in 58 out of 63 (92%) devices implanted. In 4 out of 66 (6%) devices a partial opening of the distal end occurred, and in 5 (8%) devices incomplete apposition was reported. There were 3 (5%) intraprocedural thromboembolic events managed successfully with no permanent neurological morbidity, and 4 (7%) postprocedural events. There was no mortality in this study. The initial occlusion rates in the 60 aneurysms were as follows: O'Kelly-Marotta (OKM) A in 34 (57%) cases, OKM B in 15 (25%) cases, OKM C in 6 (10%) cases, and OKM D in 5 (8%) cases.
CONCLUSIONS: Our study demonstrated that the use of the new flow diverter Silk Vista for the treatment of intracranial aneurysms is feasible and technically safe. © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  aneurysm; flow diverter; technology

Year:  2021        PMID: 33832971     DOI: 10.1136/neurintsurg-2021-017421

Source DB:  PubMed          Journal:  J Neurointerv Surg        ISSN: 1759-8478            Impact factor:   5.836


  2 in total

1.  Safety and Efficacy of Cangrelor Among Three Antiplatelet Regimens During Stent-Assisted Endovascular Treatment of Unruptured Intracranial Aneurysm: A Single-Center Retrospective Study.

Authors:  Mourad Cheddad El Aouni; Elsa Magro; Mohamed Abdelrady; Michel Nonent; Jean Christophe Gentric; Julien Ognard
Journal:  Front Neurol       Date:  2022-03-04       Impact factor: 4.003

2.  Treatment of Intracranial Aneurysms Using the New Silk Vista Flow Diverter: Safety Outcomes at Short-Term Follow-Up.

Authors:  José M Pumar; Antonio Mosqueira; Jorge Olier; Claudio Rodriguez-Fernandez; Pedro Vega; Eva Gonzalez-Diaz
Journal:  Front Neurol       Date:  2021-07-09       Impact factor: 4.003

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.